Fluphenazine decanoate: a clinical problem?

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Medicine

Background:

• Schizophrenia treatment often involves antipsychotic medications.
• Long-acting injectable (LAI) antipsychotics offer an alternative to daily oral dosing.
• The impact of LAI antipsychotics on overall medication dosage requires further investigation.

Purpose of the Study:

• To compare the total antipsychotic medication dosage in schizophrenic patients receiving fluphenazine decanoate versus oral antipsychotics.
• To identify potential differences in medication burden between injectable and oral antipsychotic treatment in schizophrenia.

Main Methods:

• Retrospective chart review of 40 randomly selected schizophrenia patients.
• Comparison of 20 patients on fluphenazine decanoate with 20 patients on oral antipsychotics only.
• Calculation of chlorpromazine equivalent doses to standardize antipsychotic exposure.

Main Results:

• The fluphenazine decanoate group exhibited a significantly higher mean chlorpromazine equivalent dose (2010 +/- 836) compared to the oral medication group (373 +/- 384).
• No significant differences were observed in other studied variables between the two groups.
• This suggests a potential for increased overall antipsychotic load with fluphenazine decanoate.

Conclusions:

• The use of fluphenazine decanoate may be associated with a higher overall antipsychotic dose in a subset of schizophrenia patients.
• Clinicians should consider total medication burden when prescribing long-acting injectable antipsychotics.
• Further research is warranted to understand the implications of higher antipsychotic doses in patients on injectable formulations.